The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Open accessAbstract
Proliferation and survival of Hodgkin and Reed/Sternberg (HRS) cells, the malignant cells of classical Hodgkin lymphoma (cHL), are dependent on constitutive activation of nuclear factor κB (NF-κB). NF-κB activation through various stimuli is negatively regulated by the zinc finger protein A20. To determine whether A20 contributes to the pathogenesis of cHL, we sequenced TNFAIP3, encoding A20, in HL cell lines and laser-microdissected HRS cells from cHL biopsies. We detected somatic mutations in 16 out of 36 cHLs (44%), including missense mutations in 2 out of 16 Epstein-Barr virus–positive (EBV+) cHLs and a missense mutation, nonsense mutations, and frameshift-causing insertions or deletions in 14 out of 20 EBV− cHLs. In most mutated cases, both TNFAIP3 alleles were inactivated, including frequent chromosomal deletions of TNFAIP3. Reconstitution of wild-type TNFAIP3 in A20-deficient cHL cell lines revealed a significant decrease in transcripts of selected NF-κB target genes and caused cytotoxicity. Extending the mutation analysis to primary mediastinal B cell lymphoma (PMBL), another lymphoma with constitutive NF-κB activity, revealed destructive mutations in 5 out of 14 PMBLs (36%). This report identifies TNFAIP3 (A20), a key regulator of NF-κB activity, as a novel tumor suppressor gene in cHL and PMBL. The significantly higher frequency of TNFAIP3 mutations in EBV− than EBV+ cHL suggests complementing functions of TNFAIP3 inactivation and EBV infection in cHL pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shared Principles in NF-κB Signaling
Hayden, M. S., & Ghosh, S. (2008) · Cell · doi:10.1016/j.cell.2008.01.020 · Cited by 4,494
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., et al. (2004) · Nature · doi:10.1038/nature02794 · Cited by 1,856
Failure to Regulate TNF-Induced NF-κB and Cell Death Responses in A20-Deficient Mice
Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M., Lodolce, J. P., & Ma, A. (2000) · Science · doi:10.1126/science.289.5488.2350 · Cited by 1,409
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses
Boone, D. L., Turer, E. E., Lee, E. G., Ahmad, R.-C., Wheeler, M. T., Tsui, C., Hurley, P., Chien, M., Chai, S., Hitotsumatsu, O., et al. (2004) · Nature Immunology · doi:10.1038/ni1110 · Cited by 1,090
Szymczak, A. L., Workman, C. J., Wang, Y., Vignali, K. M., Dilioglou, S., Vanin, E. F., & Vignali, D. A. A. (2004) · Nature Biotechnology · doi:10.1038/nbt957 · Cited by 1,059
Traenckner, E. B., Pahl, H. L., Henkel, T., Schmidt, K. N., Wilk, S., & Baeuerle, P. A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07287.x · Cited by 1,013
Ea, C.-K., Deng, L., Xia, Z.-P., Pineda, G., & Chen, Z. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.026 · Cited by 1,000
Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119849 · Cited by 761
Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation
Wu, C.-J., Conze, D. B., Li, T., Srinivasula, S. M., & Ashwell, J. D. (2006) · Nature Cell Biology · doi:10.1038/ncb1384 · Cited by 608
Cited by
Breaking the chains: structure and function of the deubiquitinases
Komander, D., Clague, M. J., & Urbé, S. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2731 · Cited by 1,969
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationMutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Compagno, M., Lim, W. K., Grunn, A., Nandula, S. V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., et al. (2009) · Nature · doi:10.1038/nature07968 · Cited by 1,038
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
A20 in inflammation and autoimmunity
Catrysse, L., Vereecke, L., Beyaert, R., & van Loo, G. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.005 · Cited by 493
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology
Vereecke, L., Beyaert, R., & van Loo, G. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.05.007 · Cited by 482
Pathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Epstein–Barr virus-associated lymphomas
Shannon-Lowe, C., Rickinson, A. B., & Bell, A. I. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0271 · Cited by 428
Steidl, C., Connors, J. M., & Gascoyne, R. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8401 · Cited by 374
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
Reichel, J., Chadburn, A., Rubinstein, P. G., Giulino-Roth, L., Tam, W., Liu, Y., Gaiolla, R., Eng, K., Brody, J., Inghirami, G., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610436 · Cited by 337
Spina, V., Bruscaggin, A., Cuccaro, A., Martini, M., Di Trani, M., Forestieri, G., Manzoni, M., Condoluci, A., Arribas, A., Terzi-Di-Bergamo, L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-812073 · Cited by 332
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Kim, S.-W., Ramasamy, K., Bouamar, H., Lin, A.-P., Jiang, D., & Aguiar, R. C. T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200081109 · Cited by 318
Huang, Y., de Reyniès, A., de Leval, L., Ghazi, B., Martin-Garcia, N., Travert, M., Bosq, J., Brière, J., Petit, B., Thomas, E., et al. (2010) · Blood · doi:10.1182/blood-2009-05-221275 · Cited by 313
Deubiquitinase inhibition as a cancer therapeutic strategy
D'Arcy, P., Wang, X., & Linder, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 310
Mechanisms and pathways of innate immune activation and regulation in health and cancer
Cui, J., Chen, Y., Wang, H. Y., & Wang, R.-F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.979640 · Cited by 309
Signaling to NF- B: Regulation by Ubiquitination
Wertz, I. E., & Dixit, V. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003350 · Cited by 300
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3487 · Cited by 288
Küppers, R., Engert, A., & Hansmann, M.-L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61245 · Cited by 286
Self-citationAldinucci, D., Gloghini, A., Pinto, A., De Filippi, R., & Carbone, A. (2010) · The Journal of Pathology · doi:10.1002/path.2711 · Cited by 275
The Ubiquitin Modifying Enzyme A20 Restricts B Cell Survival and Prevents Autoimmunity
Tavares, R. M., Turer, E. E., Liu, C. L., Advincula, R., Scapini, P., Rhee, L., Barrera, J., Lowell, C. A., Utz, P. J., Malynn, B. A., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.07.017 · Cited by 271
Deubiquitinases in the regulation of NF-κB signaling
Harhaj, E. W., & Dixit, V. M. (2011) · Cell Research · doi:10.1038/cr.2010.166 · Cited by 261
Regulation of NF‐κB by deubiquitinases
Harhaj, E. W., & Dixit, V. M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01100.x · Cited by 260
Bellail, A. C., Olson, J. J., Yang, X., Chen, Z. J., & Hao, C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0172 · Cited by 113
“Somatic mutations in TNFAIP3, the gene encoding the A20 protein, have been identified in lymphomas (44, 45).”
BackgroundWang, S., Wen, F., Wiley, G. B., Kinter, M. T., & Gaffney, P. M. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003750 · Cited by 98
Choi, J., Lee, K., Ingvarsdottir, K., Bonasio, R., Saraf, A., Florens, L., Washburn, M. P., Tadros, S., Green, M. R., & Busino, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0084-5 · Cited by 50
High-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
Metadata
- Authors
- Schmitz, R., Hansmann, M.-L., Bohle, V., Martin-Subero, J. I., Hartmann, S., Mechtersheimer, G., Klapper, W., Vater, I., Giefing, M., Gesk, S., Stanelle, J., Siebert, R., & Küppers, R.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2009-04-20
- Volume
- 206
- Issue
- 5
- Pages
- 981-989
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2097583243
- Cited by
- 481
- References
- 29
- FWCI
- 30.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.